We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
신규 편입 · 포트폴리오 비중 0.04%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $298.78 · 17 analysts
Stored first · Google News · Yahoo Finance (English)
Enterprise value to EBITDA forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – DUS:A710 TradingView
Price to sales forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Price to sales forward of Ascendis Pharma A/S – NASDAQ:ASND TradingView
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24%
Ascendis Pharma : ASND - 24/7 Wall St.
Ascendis Pharma : ASND 24/7 Wall St.
Why Crinetics Stock Soared 99% This Week
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 30. | After market close (AMC) | $0.7 | — | — | $331.97M | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Citigroup | — | Initiate coverage | — → Buy | — | Citigroup: Buy |
| 2026. 05. 16. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 05. 11. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 08. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 04. 16. | B of A Securities | — | Maintain | Buy → Buy | — | B of A Securities: Buy |
| 2026. 04. 09. | Wedbush | — | Maintain | Outperform → Outperform | — | Wedbush: Outperform |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 247,892 | $52.86M | 0.08% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 220,341 | $50.4M | 0.04% | — | New position |